MX358726B - Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales. - Google Patents

Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.

Info

Publication number
MX358726B
MX358726B MX2013015146A MX2013015146A MX358726B MX 358726 B MX358726 B MX 358726B MX 2013015146 A MX2013015146 A MX 2013015146A MX 2013015146 A MX2013015146 A MX 2013015146A MX 358726 B MX358726 B MX 358726B
Authority
MX
Mexico
Prior art keywords
treatment
biomarcator
carcinoma
renal cells
predictive survival
Prior art date
Application number
MX2013015146A
Other languages
English (en)
Other versions
MX2013015146A (es
Inventor
Antonio Anderson Abraham
M Weinreich David
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2013015146A publication Critical patent/MX2013015146A/es
Publication of MX358726B publication Critical patent/MX358726B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para predecir y tratar el beneficio clínico de paciente con carcinoma de células renales humanas previo de su tratamiento con un inhibidor de VEGFR y un inhibidor de Ang2.
MX2013015146A 2011-06-29 2012-06-28 Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales. MX358726B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161502686P 2011-06-29 2011-06-29
PCT/US2012/044673 WO2013003606A1 (en) 2011-06-29 2012-06-28 Predictive biomarker of survival in the treatment of renal cell carcinoma

Publications (2)

Publication Number Publication Date
MX2013015146A MX2013015146A (es) 2014-03-27
MX358726B true MX358726B (es) 2018-09-03

Family

ID=46545468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015146A MX358726B (es) 2011-06-29 2012-06-28 Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.

Country Status (7)

Country Link
US (1) US9151761B2 (es)
EP (1) EP2726088B1 (es)
JP (1) JP6069312B2 (es)
AU (1) AU2012275346B2 (es)
CA (1) CA2840212A1 (es)
MX (1) MX358726B (es)
WO (1) WO2013003606A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057367A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗体及び眼科に使用する方法
BR112017009790A2 (pt) * 2014-11-10 2017-12-19 Hoffmann La Roche anticorpos direcionados ao anti-ang2 e métodos de uso
AU2015345320A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Anti-IL-1beta antibodies and methods of use
WO2016209972A1 (en) * 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
WO2017110764A1 (ja) * 2015-12-24 2017-06-29 公益財団法人がん研究会 マルチキナーゼ阻害剤の有効性と安全性を予測する検査方法、検査キット、及びバイオマーカー
ES2908848T3 (es) * 2016-01-25 2022-05-04 Sanofi Sa Método de predicción del resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer midiendo el nivel de un biomarcador de plasma

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5871723A (en) 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US6248327B1 (en) 1998-09-11 2001-06-19 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
EP1962903B1 (en) * 2005-12-15 2013-03-13 MedImmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP2089425B1 (en) 2006-11-10 2011-08-17 CovX Technologies Ireland Limited Anti-angiogenic compounds
EP2132572A4 (en) * 2007-03-20 2010-04-14 Apocell Inc EVALUATION OF RTK TARGET MEDICINES
MX2010012290A (es) * 2008-05-14 2011-02-21 Amgen Inc Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.

Also Published As

Publication number Publication date
CA2840212A1 (en) 2013-01-03
US9151761B2 (en) 2015-10-06
MX2013015146A (es) 2014-03-27
EP2726088B1 (en) 2019-01-02
JP6069312B2 (ja) 2017-02-01
US20140348824A1 (en) 2014-11-27
AU2012275346B2 (en) 2016-03-17
JP2014521070A (ja) 2014-08-25
WO2013003606A1 (en) 2013-01-03
AU2012275346A1 (en) 2013-12-19
EP2726088A1 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
EA201101522A1 (ru) Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10)
MX358726B (es) Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
GT201500051A (es) Inhibidores de glucosilceramida sintasa
IN2015DN03795A (es)
HUE036872T2 (hu) Kiméra, antigénreceptor-módosított T-sejt alkalmazása rák kezelésére
DK3130923T3 (da) Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
CR20110560A (es) Métodos de tratamiento para tumores sólidos
PL2768493T3 (pl) Fitokannabinoidy do stosowania w leczeniu raka piersi
IL237592B (en) Methods of expanding and assessing b cells and using expanded b cells to treat disease
CR20130517A (es) Tratamientos combinados para neoplasias hematológicas malignas
PL3321355T3 (pl) Sposoby i kompozycje do klinicznego pozyskiwania komórek alogenicznych oraz zastosowania terapeutyczne
PL3023788T3 (pl) Kompozycje neoantygenów specyficznych wobec nowotworu do zastosowania w leczeniu nowotworów
IN2014DN06104A (es)
MX2020008031A (es) Composiciones y metodos para reducir el contenido de alcohol en sangre.
PL2780036T3 (pl) Kompozycje nanocząstek do generowania regulatorowych komórek t i leczenie chorób autoimmunologicznych i innych przewlekłych stanów zapalnych
PH12013501894A1 (en) Human tissue factor antibody and uses thereof
EA201400178A1 (ru) Лечение рака молочной железы
UY34132A (es) Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.
IL215467A (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
AU2018256561A1 (en) Aminosteroids for the treatment of a PTP1B associated disease
MX2012002909A (es) Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
PL2742356T3 (pl) Środki prognostyczne w leczeniu nowotworów
AU342936S (en) Insole
GB2510524A (en) Pulmonary hypertension

Legal Events

Date Code Title Description
FG Grant or registration